Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
about
Meglitinide analogues for type 2 diabetes mellitusEffect of the combination of mitiglinide and metformin on glycemic control in patients with type 2 diabetes mellitus.Quo vadis nateglinide? Ten-year perspective.Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetesUpdated review: improved glycemic control with repaglinide-metformin in fixed combination for patients with type 2 diabetesPharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine.A review of nateglinide in the management of patients with type 2 diabetes.Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose.The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus.Self-monitoring of blood glucose in diabetes mellitus: arguments for an individualized approach.Add-on therapies to metformin for type 2 diabetes.Control of postprandial glucose levels with insulin in type 2 diabetes.Repaglinide: a review of its use in type 2 diabetes mellitus.Therapeutic choices, and the nurse practitioner's role, in type 2 diabetes when metformin alone is no longer enough.Pharmacologic treatment of type 2 diabetes: oral medications.The effects of sulfonylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: a meta-analysis of randomized controlled trials.Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies.Progressing From Metformin to Sulfonylureas or Meglitinides.Fixed combination of repaglinide and metformin in the management of type 2 diabetes.Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update.Severe thrombocytopenia due to repaglinide in a patient with type 2 diabetes.Applying area-under-the-curve analysis to enhance interpretation of response profiles: an application to sleep quality scores in patients with fibromyalgia.Meglitinides increase the risk of hypoglycemia in diabetic patients with advanced chronic kidney disease: a nationwide, population-based study.Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial.
P2860
Q24245352-7762F198-2BC1-40F3-801B-F4B76DD93DF1Q33558365-596906D9-F9FA-4138-A19D-A4CBA6E628FFQ33975364-7234AB5C-F342-4119-9948-7C683DE5A9FFQ34592210-B3D96214-246D-4339-AB13-75A1724FC9BEQ34606070-D8463DD4-84F4-4D27-8809-1716E6ABCC4AQ36139133-4CCB7956-C73F-4268-96E4-9C190B7D6ED8Q36441465-9728B3CF-D2CF-44FA-BCE4-E5161D3875DAQ36596836-7CABA6BC-D81C-4B6A-BA4E-EBC99AF2967BQ37223610-66B7644A-4B31-49C9-AED3-BB9B99AD92C2Q37321871-935CC5C2-1EC7-46CE-9F11-E41E6D00FB90Q37405143-F4361B29-1C1F-4966-A9AE-828CBE85FD7CQ37818234-1D281403-4B1A-4EE1-BD47-034768766B0BQ37890790-E1EC9DF2-B7D8-4B80-98EF-F680F7587AFDQ37977979-311CB7FA-02EB-4562-9CEF-BF48A6085928Q38008004-4343A5F7-757C-4BF3-9C74-42C66D8AE6E7Q38350347-722C5234-2C56-4580-9238-A1A6BAAB92A3Q38408346-6B2E3041-A254-4884-B709-D1C5276AF826Q38442816-A564FFE6-888C-471F-A309-3DFAFF1B9D9EQ38952882-F31F561A-74A5-47B0-9671-BAA7661C16CEQ42178891-3254C94C-800F-4994-9522-5D2B9C985C7CQ42253351-29478E12-9FC5-4AAF-A161-BE1E45449AE8Q43242160-359B76D6-7004-415E-977A-CC5744195B38Q43728541-C9A22914-8BCA-456E-8A77-11DAD1E4D363Q47145533-BBC4EA3C-D91D-4F0F-8A3A-F221137EC521Q51468978-A4CF4C42-21D6-45FF-BBF8-78B62E5F6302
P2860
Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Efficacy and safety of combina ...... us nateglinide plus metformin.
@en
Efficacy and safety of combina ...... us nateglinide plus metformin.
@nl
type
label
Efficacy and safety of combina ...... us nateglinide plus metformin.
@en
Efficacy and safety of combina ...... us nateglinide plus metformin.
@nl
prefLabel
Efficacy and safety of combina ...... us nateglinide plus metformin.
@en
Efficacy and safety of combina ...... us nateglinide plus metformin.
@nl
P2093
P1433
P1476
Efficacy and safety of combina ...... sus nateglinide plus metformin
@en
P2093
Janet McGill
Leslie Klaff
Paula M Hale
Philip Raskin
Priscilla Hollander
Repaglinide vs. Nateglinide Metformin Combination Study Group
Stephen A South
P304
P356
10.2337/DIACARE.26.7.2063
P407
P577
2003-07-01T00:00:00Z